Results for this period
Third quarter1 January 2026 to 30 September 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue was ¥22 million, down 72.2% year on year, while the operating loss was ¥3,916 million, compared with an operating loss of ¥2,333 million in the same period of the previous year. Research and development expenses were ¥2,875 million, compared with ¥1,533 million in the same period of the previous year. No specific reason was given for the decline in revenue.
Material events, etc. are disclosed. However, the company determined that there is currently no material uncertainty regarding the going concern assumption.
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026 to 30 September 2026 |
| Net Sales | ¥22 million (YoY -72.2%) |
| Operating profit | ¥-3,916 million |
| Profit attributable to owners of the parent | ¥-4,542 million |
| Net income per share | (¥34.39) |
| Equity ratio | End of the current fiscal period 29.2 / End of previous period 28.7 |
| Total assets | ¥22,831 million |
| Net assets | ¥6,683 million |
| Cash flows from operating activities | ¥-4,079 million |
| Cash flows from investing activities | ¥-1,363 million |
| Cash flows from financing activities | ¥7,153 million |
| Cash and cash equivalents at end of period | ¥7,423 million |
| Full-year earnings forecast | Net Sales Not disclosed / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed / Reason Not stated because a reasonable earnings forecast cannot currently be calculated |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Depreciation and amortization | ¥239 million |
| Disclosure regarding the going concern assumption | Material events, etc. are disclosed. However, the company determined that there is currently no material uncertainty regarding the going concern assumption. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | Added: 0 companies; excluded: 0 companies |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | No (target: Not disclosed) |
| Issued Shares at Period-End | 135,545,600 |
| Treasury Shares at Period-End | 333 |
| Factors Behind Changes in Business Performance | Revenue was ¥22 million, down 72.2% year on year, while the operating loss was ¥3,916 million, compared with an operating loss of ¥2,333 million in the same period of the previous year. Research and development expenses were ¥2,875 million, compared with ¥1,533 million in the same period of the previous year. No specific reason was given for the decline in revenue. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company explained that it will not disclose a full-year earnings forecast because there are many uncertain factors affecting performance, including business alliances and the acquisition of new drug discovery seeds, making it difficult to calculate a reasonable forecast. It also stated that it is advancing research and development during the fiscal year, with research and development expenses totaling ¥2,875 million.